Trial Profile
A Phase IIa, Prospective, Randomized, Blinded, Intra-Subject Controlled, Single Dose, Dose Escalation Study of Antizol® for Mitigation of Acetaldehyde Related Toxicity in Human Subjects With Symptoms of Inborn Altered Ethanol Metabolism With Concomitant Ethanol Exposure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fomepizole (Primary)
- Indications Metabolic disorders
- Focus Adverse reactions
- Sponsors Raptor Pharmaceuticals Corp
- 13 May 2014 New trial record